АНДЕРСОН Аннализа Сибил (US),ХОЙСЕТ Сюзан Кэй (US),ДЖЕНСЕН Кэтрин Юте (US),МОРАН Джастин Кейт (US),РАППЕН Марк Е. (US)
申请号：
RU2014136401
公开号：
RU2014136401A
申请日:
2013.03.06
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. An isolated polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 71, wherein the first twenty amino acid residue sequence does not contain tsisteina.2. An isolated polypeptide according to claim 1, characterized in that the polypeptide comprises an amino acid sequence in positions 1-184 SEQ ID NO:. 71.3. An isolated polypeptide according to claim 1, characterized in that the polypeptide comprises at least 6 contiguous amino acids from amino acid sequence position 185-254 SEQ ID NO:. 71.4. An isolated polypeptide according to Claim. 1, characterized in that the polypeptide is nepiruvilirovannym.5. An isolated polypeptide according to Claim. 1, characterized in that the polypeptide is nelipidirovannym.6. An isolated polypeptide according to Claim. 1, characterized in that the polypeptide is immunogennym.7. An isolated polypeptide according to claim 1, characterized in that the amino acid sequence consists of the sequence shown in SEQ ID NO:. 71.8. An immunogenic composition comprising a polypeptide according to any one of claims. 1-7.9. An immunogenic composition according to claim. 8, characterized in that it further comprises a polypeptide A12.10. An immunogenic composition according to claim. 8, characterized in that it further comprises a polypeptide A05.11. An immunogenic composition according to claim. 8, characterized in that it further comprises V09.12 polypeptide. An immunogenic composition according to claim. 8, characterized in that it further comprises V44.13 polypeptide. An immunogenic composition according to claim. 8, characterized in that it further includes A12, B09, and V44.14 polypeptide. An immunogenic composition according to claim. 8, characterized in that it further includes A05, A12, B09, and V44.15 polypeptide. An immunogenic composition according to any one of claims. 9-14, wherein each polypeptide is nelipidirovannym.16. An immunogenic composition according to any one of claims. 9-14, wherein each polypeptide
